Forty-seven patients with stabile SLE were randomised to continue hydroxychloroquine (n=25) or receive placebo (n=22) for 24 weeks 1. The risk of relapse was 2.5 times higher in the placebo recipients (95% CI 1.08 to 5.58) compared to those who continued to receive hydroxychloroquine (activation of the disease was observed in 16 patients in the placebo group and 9 patients in the hydroxychloroquine group).
For a review see reference 2.
Comment: The quality of evidence is downgraded by sparse data and potential publication bias (no systematic literature search was performed).
Primary/Secondary Keywords